Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank

Erichsen, Rune; Lash, Timothy L.; Hamilton‐Dutoit, Stephen; Bjerregaard, Beth; Vyberg, Mogens; Pedersen, Lars

doi:10.2147/clep.s9908

Cited by 280 publications

(279 citation statements)

References 6 publications

Supporting

Mentioning

278

Contrasting

Order By: Relevance

“…Using the civil registration number we linked the data from the national database with data from the National Pathology Registry, the National Registry of Patients and the Danish Civil Registration System. The National Pathology Registry holds detailed data on all pathology specimens analysed in Denmark since 1997 [12]. The National Registry of Patients contains data on all discharges from all non psychiatric hospitals in Denmark since 1977 [13].…”

Section: Methodsmentioning

confidence: 99%

Enforcing centralization for gastric cancer in Denmark

Jensen

Nielsen

Mortensen

et al. 2010

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Enforcing centralization for gastric cancer in Denmark

Jensen

Nielsen

Mortensen

et al. 2010

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

“…We conducted a large nationwide population-based cohort study, with complete follow-up and highly valid data for thyroid disease (21,23,33) and breast cancer diagnoses (34,35). The higher incidence of hyperthyroidism compared with hypothyroidism is in agreement with previous studies (36), as is the increased incidence of thyroid disease over time (37).…”

Section: European Journal Of Endocrinologymentioning

confidence: 99%

Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study

Søgaard

Farkas

Ehrenstein

et al. 2016

European Journal of Endocrinology

126

111

View full text Add to dashboard Cite

Objective: The association between thyroid disease and breast cancer risk remains unclear. We, therefore examined the association between hypothyroidism, hyperthyroidism and breast cancer risk. Design: This was a population-based cohort study. Methods: Using nationwide registries, we identified all women in Denmark with a first-time hospital diagnosis of hypothyroidism or hyperthyroidism, 1978-2013. We estimated the excess risk of breast cancer among patients with hypothyroidism or hyperthyroidism compared with the expected risk in the general population, using standardized incidence ratios (SIRs) as a measure of risk ratio. Breast cancer diagnoses in the first 12 months following diagnosis of thyroid disease were excluded from the calculations to avoid diagnostic work-up bias. Results: We included 61 873 women diagnosed with hypothyroidism and 80 343 women diagnosed with hyperthyroidism. Median follow-up time was 4.9 years (interquartile range (IQR): 1.8-9.5 years) for hypothyroidism and 7.4 years (IQR: 3.1-13.5 years) for hyperthyroidism. Hyperthyroidism was associated with a slightly increased breast cancer risk compared with the general population (SIR: 1.11, 95% CI: 1.07-1.16), which persisted beyond 5 years of follow-up (SIR: 1.13, 95% CI: 1.08-1.19). In comparison, hypothyroidism was associated with a slightly lower risk of breast cancer (SIR: 0.94, 95% CI: 0.88-1.00). Stratification by cancer stage at diagnosis, estrogen receptor status, age, comorbidity, history of alcohol-related disease and clinical diagnoses of obesity produced little change in cancer risk. Conclusions: We found an increased risk of breast cancer in women with hyperthyroidism and a slightly decreased risk in women with hypothyroidism indicating an association between thyroid function level and breast cancer risk.

show abstract

“…To identify patients with recurrent disease, additional searches were performed in the Danish National Pathology Registry [9] and the National Patient Registry [10]. The data construction and the external and internal validity of the databases have been described in detail previously [7].…”

Section: Data Sources and Variablesmentioning

confidence: 99%

Detection of recurrence in early stage endometrial cancer – the role of symptoms and routine follow-up

et al. 2017

View full text Add to dashboard Cite

Background: Considerable controversy remains as to the optimal organization of endometrial cancer follow-up. Aim: To evaluate the relationship between the way recurrence was detected and survival after treatment for endometrial cancer. Further, to identify characteristics associated with a pre-scheduled examination in women with symptomatic recurrence. Material and methods: All women with early stage endometrial cancer during [2005][2006][2007][2008][2009] were included in a population-based historical cohort derived from the Danish Gynecological Cancer Database. Women diagnosed with recurrence within three years after primary surgery and the mode of recurrence detection were identified from hospital charts: asymptomatic recurrence detected at regular follow-up, symptomatic recurrence detected at regular follow-up or symptomatic recurrence detected in between follow-up. Survival of women with symptomatic and asymptomatic disease was compared. Furthermore, characteristics associated with self-referral as compared to presenting symptoms at regular follow-ups were identified using univariate analyses. Results: In total, 183 cases of recurrence (7%) were identified in the cohort of 2612 women. Of these, 65.5% were symptomatic with vaginal bleeding as the most prevalent symptom. Asymptomatic women had a significantly better three-year survival rate compared to symptomatic women (80.3% vs. 54.3%, p < 0.01). A total of 2.3% of the entire population had an asymptomatic recurrence. Women diagnosed at a pre-scheduled visit due to symptoms had a higher educational level (p ¼ 0.03) and more often high-risk disease (p ¼ 0.02) than symptomatic women diagnosed at regular follow-up. Conclusion: Early stage endometrial cancer carries a low risk of recurrence. Survival appears to be superior in asymptomatic patients, but length-time bias, i.e. the effect of aggressive tumor biology in symptomatic recurrences, may bias results in non-randomized controlled trials. Well educated patients with symptoms of recurrence more often sought medical attendance compared to less educated counterparts. This should be considered if patient-initiated follow-up is the standard care.

show abstract

Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank

Cited by 280 publications

References 6 publications

Enforcing centralization for gastric cancer in Denmark

Enforcing centralization for gastric cancer in Denmark

Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study

Detection of recurrence in early stage endometrial cancer – the role of symptoms and routine follow-up

Contact Info

Product

Resources

About